All In Biotech

Drug Trial Radar · NCT04559230

Sacituzumab Govitecan in Recurrent Glioblastoma

A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jan 6, 2022

Primary completion

Aug 2027

Study completion Feb 2028

Sponsor

Sponsor type
Academic, hospital or other
First posted
Sep 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.

Conditions

  • Recurrent Glioblastoma

Interventions

  • Sacituzumab GovitecanDrug

    Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio · Recruiting

  • Texas Oncology Austin

    Austin, Texas · Recruiting

  • University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.